LONDEN –(BUSINESS WIRE)–

BTG plc (LSE: BTG), het wereldwijde gezondheidszorgbedrijf, kondigde vandaag aan dat de eerste EKOS™ CU 4.0 units vanuit de vestiging van BTG in Bothell (Washington, VS) naar Europa zijn verscheept, waar de volledige commerciële introductie begint. Nieuwe functies van de EKOS™ CU 4.0 bevatten een interactief kleuren-touchscreen, een ingebouwde batterij en aparte poorten voor het gelijktijdig beheren van twee EKOS™-apparaten.

Deze verbeteringen vereenvoudigen de bilaterale behandeling van longembolie (PE) en diep-veneuze trombose (DVT). Met behulp van CU 4.0 kunnen artsen beide longslagaders behandelen en kunnen ze gemakkelijk twee EKOS™-apparaten tegelijkertijd bewaken en beheren.

Europese patiënten met PE’s en DVT’s zijn al met succes behandeld met EKOS™ CU 4.0 tijdens een beperkte afgifte van het product.

EKOS™ Control Unit 4.0 Simplifies Treatment of Blood Clots

LONDON–(BUSINESS WIRE)–

First commercial units are shipped to Europe

BTG plc (LSE: BTG), the global healthcare company, announced today that the first EKOS™ CU 4.0 units have been shipped from BTG’s facility in Bothell (Washington, US) to Europe, where full commercial launch will begin. New features of the EKOS™ CU 4.0 include an interactive colour touchscreen, a built-in battery and separate ports for managing two EKOS™ devices simultaneously.

These improvements simplify bilateral treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT). Using CU 4.0, physicians can treat both pulmonary arteries and can easily monitor and manage two EKOS™ devices at the same time.

European patients with PEs and DVTs have already successfully been treated with EKOS™ CU 4.0 during a limited release of the product.

Professor Nils Kucher, Director of Clinic of Angiology at University Hospital in Zurich, Switzerland said: “I’ve used EKOS™ therapy for over 10 years. This latest innovation of the technology is a big step for simplifying thrombosis treatment.”

EKOS™ is the only device to have both FDA Clearance and a CE Mark [0086] for the treatment of PE. The system includes an ultrasonic device that uses acoustic pulses, which enable quick and safe dissolution of blood clots and restore blood flow in patients with PE, DVT and peripheral arterial occlusions.

About BTG

BTG is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. We have a growing portfolio of products that advance the treatment of cancer and vascular conditions. BTG’s Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins. To learn more about BTG, please visit: btgplc.com.

EKOS is a registered trademark of EKOS Corporation, a BTG International group company. BTG and the BTG roundel logo are registered trademarks of BTG International LTD.

Product availability varies by country. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. Prior to use, please refer to the applicable Instructions for Use (IFU) for complete product indications, contraindications, warnings, and precautions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181105006071/en/

Contacts

BTG
Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605
or
Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536
or
Chris Sampson, Corporate Communications Director
+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178
or
FTI Consulting
Ben Atwell/Simon Conway +44 (0)20 3727 1000